EuMederis Pharmaceuticals, Inc. is a seed-phase drug discovery company focused on peptide pharmaceuticals with improved bioavailability and dosing schedules.
Initial products are directed at indications in pain, in control of osteoporosis, and in the reversal of the inflammatory component of the metabolic syndrome. EuMederis has already undertaken proof of concept studies entailing compound synthesis and in vivo testing through our highly-regarded network of partners in the contract research organization world.
These pharmaceutical candidates make use of a broadly-based, proprietary technology (EuPort) developed by our Founder, based on his many years of successful research on peptide drug candidates.
Our current pipeline contains preclinical candidates for each of the three clinical indications cited above.
Because of the breadth of application for our drug design technology, the EuMederis Business Plan anticipates outlicensing certain preclinical pharmaceutical candidates to drug development partners as well as the incorporation of a highly-focused, drug development unit for our in-house pipeline.
We plan to operate in a largely virtual mode, identifying clinical development candidates using our proprietary technology and pursuing clinical studies through our network of CRO partners.
EuMederis currently seeks:
Founding CEO and CSO
John J. Nestor, Jr., Ph.D.
Dr. Nestor has more than 30 years of pharmaceutical industry experience in drug discovery and scientific management, much of that time at the VP level in major pharma (Syntex, Roche).
He is a Founder of three drug discovery companies and lead inventor of >10 compounds selected for clinical development, including three that are marketed pharmaceuticals (Valcyte®, Roche; Orgalutran®, Merck; Synarel®, Pfizer).